header image

Take a look through our annual reports.

How to contact us for media/press enquiries.

Have a comment or question? Get in touch.

News

Octapharma donates 30.5 million international units of its medicine Nuwiq® to treat people with haemophilia in developing countries

11-21-2017

Lachen, Switzerland, November 21st, 2017: Octapharma is pleased to announce the completion of a charitable donation of 30.5 million international units of its human cell-line derived recombinant factor VIII product, Nuwiq®, in...

Octapharma USA Grant Supports Mission of First Hemophiliac to Climb the Seven Summits of the World

11-02-2017

Hoboken, New Jersey, October 31st 2017: Octapharma USA has provided a grant to support the final leg of the inspirational journey of Chris Bombardier, who hopes to become the first person with severe Hemophilia to climb...

Octapharma USA Grant Supports Mission of First Hemophiliac to Climb the Seven Summits of the World

10-31-2017

Octapharma Partnership with Mountain Climber will Culminate with Climb of Mount Vinson & Release of Documentary

Octapharma USA Sponsors NHF Annual Meeting, Shares Inspirational Bleeding Disorders Community Achievements

08-31-2017

Hoboken, New Jersey, August 29th 2017: Octapharma USA sponsored the National Hemophilia Foundation’s 69th Annual Meeting in Chicago and provided a patient symposium sharing the inspirational stories of three young men with...

Octapharma USA Sponsors NHF Annual Meeting, Shares Inspirational Bleeding Disorders Community Achievements

08-29-2017

HOBOKEN, N.J. (August 29, 2017) – Octapharma USA sponsored the National Hemophilia Foundation’s 69th Annual Meeting in Chicago and provided a patient symposium sharing the inspirational stories of three young men with bleeding...

Octapharma USA Announces FDA Approval of NUWIQ® New Product Strengths, Expanding Hemophilia A Patient Treatment Options

08-23-2017

New Higher Vial Strengths will Provide Added Dosing Flexibility & Convenience HOBOKEN, N.J. (August 21, 2017) – Octapharma USA today announced the U.S. Food and Drug Administration (FDA) has approved new product strengths...

Publication of clinical data demonstrating low immunogenicity and excellent efficacy of Nuwiq® in previously untreated patients

08-23-2017

Lachen, Switzerland, August 23rd 2017: Octapharma is delighted to announce the publication of interim data from the NuProtect study (GENA-05, NCT01712438), the first clinical data on treatment with Nuwiq® in previously...